Anavip
| Clinical data | |
|---|---|
| Trade names | Anavip |
| Other names |
|
| Identifiers | |
| PubChem SID | |
| DrugBank | |
| UNII | |
Anavip (stylized as ANAVIP) is the trade name of a snake antivenin indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.[1] [2] [3] As defined by the FDA, the proper name is crotalidae immune F(ab')2 (equine).[4] It is manufactured by Instituto Bioclon for Rare Disease Therapeutics in the United States.
Anavip is a divalent fragment antigen-binding protein, F(ab')2, derived from the blood of horses immunized with the venom of the snakes Bothrops asper and Crotalus durissus . The product is produced by pepsin digestion of horse blood plasma then purified resulting in a preparation containing >85% F(ab')2.[5]
References
[edit ]- ^ Cocchio C, Johnson J, Clifton S (January 2020). "Review of North American pit viper antivenoms". American Journal of Health-System Pharmacy. 77 (3): 175–187. doi:10.1093/ajhp/zxz278. PMID 31974558.
- ^ "Marketing authorization with orphan designation - USA". orpha.net. orphanet. Retrieved 19 August 2020.
- ^ "Highlights of Prescribing Information". U.S. Food & Drug Administration.
- ^ Research Cf (2019年10月02日). "ANAVIP". FDA.
- ^ Laboratorios Silanes S.A. de C.V. "Highlights of Prescribing Information" (PDF). Package_Insert. Retrieved 18 August 2020.
This pharmacology-related article is a stub. You can help Wikipedia by expanding it.